Cellceutix Corporation has made two significant announcements this week pertaining to Kevetrin, their flagship compound for the treatment of drug-resistant cancers. Not only has pre-clinical data produced very promising data as a therapy for breast, lung and colon cancer, the recent data as clinical trials approach this year can only be considered big news for the cancer industry. Press this week announced that:

1. Kevetrin reactivates, p53, widely regarded as the "Guardian Angel of the Human Genome" to normal anti-tumor status.

2. Kevetrin is shown to be non-genotoxic. Genotoxicity is a downfall of the majority of chemotherapies as it damages the DNA while treating the carcinoma.

Follow the link provided to read more about Cellceutix and their revolutionary compound.